Leonard S Schleifer Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

Leonard S Schleifer is Bd. Co-Chair, President & CEO of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 214,523 shares of REGN, which is worth approximately $149 Million. The most recent transaction as insider was on Dec 31, 2025, when has been sold 28,570 shares (Common Stock) at a price of $772.09 per share, resulting in proceeds of $22,058,611. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 215K

54.05% 3M change

54.05% 12M change

Total Value Held $149 Million

LEONARD S SCHLEIFER Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 31 2025	SELL Payment of exercise price or tax liability	$22,058,611 $772.09 p/Share	28,570 Reduced 11.75%	214,523 Common Stock
Dec 31 2025	BUY Exercise of conversion of derivative security	-	28,570 Added 10.52%	243,093 Common Stock
Dec 09 2025	SELL Payment of exercise price or tax liability	$108,835,768 $701.51 p/Share	155,145 Reduced 41.97%	214,523 Common Stock
Dec 09 2025	BUY Exercise of conversion of derivative security	$95,976,989 $555.67 p/Share	172,723 Added 31.84%	369,668 Common Stock
May 17 2024	SELL Open market or private sale	$22,365,181 $979.64 p/Share	22,830 Reduced 4.66%	466,877 Common Stock
May 15 2024	SELL Open market or private sale	$10,766,272 $984.03 p/Share	10,941 Reduced 2.68%	397,259 Common Stock
May 14 2024	SELL Open market or private sale	$24,490,750 $979.63 p/Share	25,000 Reduced 5.77%	408,200 Common Stock

May 13 2024	SELL Payment of exercise price or tax liability	$141,080,710 $976.79 p/Share	144,433 Reduced 25.0%	433,200 Common Stock
May 13 2024	BUY Exercise of conversion of derivative security	$81,212,510 $399.66 p/Share	203,204 Added 26.02%	577,633 Common Stock
Dec 11 2023	SELL Payment of exercise price or tax liability	$10,838,959 $844.09 p/Share	12,841 Reduced 3.32%	374,429 Common Stock
Dec 11 2023	BUY Exercise of conversion of derivative security	-	25,155 Added 6.1%	387,270 Common Stock
Nov 19 2021	SELL Payment of exercise price or tax liability	$234,142,966 $651.96 p/Share	359,137 Reduced 43.53%	465,922 Common Stock
Nov 19 2021	BUY Exercise of conversion of derivative security	$116,955,956 $224.78 p/Share	520,313 Added 44.4%	651,568 Common Stock
Aug 18 2021	SELL Open market or private sale	$130,006,006 $650.03 p/Share	200,000 Reduced 39.62%	304,746 Common Stock
Aug 06 2021	SELL Payment of exercise price or tax liability	$138,861,600 $607.51 p/Share	228,575 Reduced 31.17%	504,746 Common Stock
Aug 06 2021	BUY Exercise of conversion of derivative security	$20,812,000 $52.03 p/Share	400,000 Added 40.15%	596,176 Common Stock
May 12 2020	SELL Open market or private sale	$85,646,725 $567.49 p/Share	150,922 Reduced 24.13%	474,499 Common Stock
May 11 2020	SELL Payment of exercise price or tax liability	$92,330,516 $571.43 p/Share	161,578 Reduced 20.53%	625,421 Common Stock
May 11 2020	BUY Exercise of conversion of derivative security	$9,571,875 $30.63 p/Share	312,500 Added 30.2%	722,368 Common Stock

LSS

Leonard S Schleifer

Bd. Co-Chair, President & CEO

Tarrytown, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Value

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN

Account